A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). METHODS: 70 pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: DiPaola, Robert S, Chen, Yu-Hui, Stein, Mark, Vaughn, David, Patrick-Miller, Linda, Carducci, Michael, Roth, Bruce, White, Eileen, Wilding, George
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2010
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837641/
https://ncbi.nlm.nih.gov/pubmed/20178647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-20
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars